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anon Siegenthaler, Alain Benoît, Charles Seydoux, MD
ausanne, Switzerland
OBJECTIVES We conducted this trial to assess whether a sirolimus-eluting stent (SES) produces similar
results to a paclitaxel-eluting stent (PES) when used in the real world of interventional
cardiology.
BACKGROUND Several drug-eluting stents have been shown to exert a beneficial effect on restenosis when
used in the treatment of coronary artery disease. Any potential superiority of one drug over
the others, however, is still unknown.
METHODS To evaluate whether a PES or an SES is superior in daily practice, we randomized all patients
suitable to receive a drug-eluting stent in our institution. Clinical follow-up was obtained after
at least six months.
RESULTS A total of 202 patients were included in this trial. One hundred patients received a PES and
102 received an SES. Procedural success was 99% in both groups. Incidence of major adverse
cardiac events at follow-up (mean 7 2 months) was 4% with the PES and 6% with the SES
(p  0.8). The need for target lesion revascularization was very low in both groups (1% with
the PES and 3% with the SES).
CONCLUSIONS Our results confirm that the high success rate obtained with both stents in randomized trials
can be replicated in routine clinical practice. In this small group of patients we were unable
to show any advantage of one stent over the other. (J Am Coll Cardiol 2005;45:308–11)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.062© 2005 by the American College of Cardiology Foundation
P
B
P
r
B
(
r
o
t
t
n
a
n
w
t
a
m
v
p
c
s

dhe use of stents has significantly improved the outcome of
ercutaneous coronary intervention (PCI) (1,2). However,
espite major advances in angioplasty and stenting, in-stent
estenosis has remained a major limitation until recently.
ince 2000, drug-eluting stents have emerged as a very
romising approach in preventing restenosis, and several
ifferent compounds have been shown to have a major
mpact on both the angiographic and the clinical outcome
3–9). However, even if the randomized trials show similar
linical benefit with these drug-eluting stents when com-
ared with bare metal stents, no direct comparison between
arious devices is available, and prospective randomized data
re strongly needed. Thus, we prospectively collected all
ata pertaining to the use of the sirolimus-eluting stent
SES) and paclitaxel-eluting stent (PES) in a randomized
rospective fashion for a series of consecutive patients
reated in our institution. The trial was started as soon as the
ES became commercially available in Switzerland, with
he purpose to compare the two stents in the real world of
nterventional cardiology.
From the Service of Cardiology, Clinique Cecil, Lausanne, Switzerland. This work
as supported by the Clinique Cecil Heart Foundation.
Manuscript received September 23, 2004; revised manuscript received October 10,
004, accepted October 25, 2004.ATIENTS AND METHODS
etween April 2003 and January 2004, all patients requiring
CI and selected to receive a drug-eluting stent were
andomized in a prospective trial comparing a PES (Taxus,
oston Scientific, Maple Grove, Minnesota) with an SES
Cypher, Cordis Corp., Miami, Florida). There was no
estriction to inclusion except the preference of the patient
r our uncertainty regarding obtaining follow-up informa-
ion.
The procedure was performed via the right femoral artery
hrough a 6-F guiding catheter. The revascularization was
early always done during the same session as the diagnostic
ngiography, except for those patients with left main ste-
osis. Intravascular ultrasound was not used. Direct stenting
as allowed but was restricted to low-risk lesions and left to
he operator’s discretion. All patients were pretreated with
spirin 100 mg/day, and a minority received clopidogrel 75
g/day for five to seven days before the procedure. Intra-
enous heparin (70 U/kg) was given at the beginning of the
rocedure. If not given earlier, a 300 mg loading dose of
lopidogrel was administered at the end of the procedure. A
uccessful procedure was defined as a residual stenosis
20% without a major adverse cardiac event (MACE)
uring the in-hospital stay.
Creatine kinase, creatine kinase-MB fraction, and/or
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f the day following the procedure. A diagnosis of non–Q-
ave myocardial infarction (MI) was made if a value above
wice the upper limit of normal was measured. A 12-lead
lectrocardiogram was recorded at the end of the procedure,
nd further tracings were obtained if indicated. Patients
emained in hospital until the next day. Long-term aspirin
00 mg/day was prescribed at discharge, together with 2 to
2 months of clopidogrel 75 mg/day.
Quantitative coronary angiography evaluation was ob-
ained in multiple views. For patients with angiographic
ollow-up, restenosis was defined as a 50% or more reduc-
ion of the luminal diameter occurring within the stented
egment or the 5 mm proximal and distal to the stent.
Clinical follow-up was obtained at one and six months,
ither by a visit or by telephone contact with the patient or
is/her referring physician. Information was collected on
ital status, occurrence of MI, additional revascularization
rocedures, coronary angiography, clinical angina status,
nd current medication. As a rule, control angiography was
erformed only when clinically required (clinical or silent
schemia). Death, MI, additional PCI or coronary artery
ypass grafting to the target lesion, documented target
esion occlusion, or stent thrombosis were considered to be
MACE.
tatistics. On the basis of previous data reported with both
tents (14% of events with the PES and 6% with the SES),
he number of patients initially planned was 173 per group
80% statistical power). However, because we did not
bserve a significant difference after the first 202 patients,
e decided as clinicians that it would be acceptable to use
ne stent or the other indifferently in clinical practice,
ecause 2,936 patients would have been necessary to dem-
nstrate superiority of one device. Values are expressed as
ean SD. All tests of significance were two-tailed (Fisher
xact test, chi-square, and Mann-Whitney). Statistical sig-
ificance was assigned at the p  0.05 level.
ESULTS
atient characteristics. During the study period 405 pa-
ients were treated; 202 of these (50%) were included in the
rial. One hundred were randomized to a PES and 102 were
andomized to a SES. The baseline data are given in Tables
and 2. The two groups were comparable.
rocedure. A total of 183 patients underwent a single
rocedure (89 in the PES group and 94 in the SES group).
Abbreviations and Acronyms
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
PES  paclitaxel-eluting stent
SES  sirolimus-eluting stentorty-four patients (22%) had multivessel revascularization.
d
Sn 25 patients, all lesions were treated in a single session. In
he remaining 19, a staged procedure was performed. A
ean number of 1.5 stents/patient were implanted in both
roups (Table 2). Direct stenting was attempted in 35
atients in the PES group and in 32 patients in the SES
roup and was successful in 32 (32%) and 28 (28%) patients,
espectively.
A platelet glycoprotein IIb/IIIa inhibitor was used in 11
atients (5 %): 4 in the PES group and 7 in the SES group
p 0.6). Major in-hospital cardiac events occurred in three
atients in the PES group versus three in the SES group (p
0.9) (Table 3). Three patients in the PES group and one
able 1. Demographic Data
PES
Group
(n  100)
SES
Group
(n  102)
p
Value
ender (male/female) 83/17 79/23 0.8
ean age (yrs) 63  10 65  10 0.9
iabetes 36 33 0.8
ypertension 63 60 0.8
eredity 23 26 0.9
yperlipidemia 79 77 0.9
mokers 26 26 0.9
-vessel disease 40 36 0.7
-vessel disease 32 35 0.9
-vessel disease 28 29 0.9
revious MI 29 33 0.8
revious PTCA 34 28 0.5
revious CABG 15 22 0.4
table angina or
silent ischemia
86 84 0.9
nstable angina 14 18 0.7
ABG  coronary artery bypass grafting; MI  myocardial infarction; PES 
aclitaxel-eluting stent; PTCA  percutaneous transluminal coronary angioplasty;
ES  sirolimus-eluting stent.
able 2. Angiographic Data
PES
Group
(n  100)
SES
Group
(n  102)
p
Value
AD 41 42 0.9
iagonal 3 2 0.9
CA 32 32 0.9
Cx 19 15 0.6
nprotected left main 2 5 0.4
VG 3 5 0.7
IMA 1 0 0.9
e novo 94 97 0.9
SR 6 3 0.5
eference diameter 3.2  0.2 3.2  0.1 0.7
LD pre-procedure (mm) 0.8  0.3 0.9  0.2 0.5
LD post-procedure (mm) 2.9  0.5 2.9  0.4 0.7
stenosis pre-procedure 72 70 0.9
stenosis post-procedure 5 5 0.8
umber of stents/pts 1.5 1.5 0.6
ultiple stents 29 38 0.5
ultivessel PCI 18 26 0.4
irect stenting 32 28 0.7
SR  in-stent restenosis; LAD  left anterior descending artery; LCx  left
ircumflex; LIMA  left internal mammary artery; MLD  minimal lumen
iameter; PCI  percutaneous coronary intervention; RCA  right coronary artery;
VG  saphenous vein graft; other abbreviations as in Table 1.
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Randomized Comparison of Drug-Eluting Stents January 18, 2005:308–11n the SES group had a creatine kinase rise (non–Q-wave
cute MI) and one in the SES group had a Q-wave MI.
here was no hospital death, and only one patient from the
ES group required emergency repeat percutaneous revas-
ularization for persistent chest pain because of a large distal
issection. Neither acute (24 h) nor subacute (24 h to 30
ays) stent thrombosis was observed in either group. The
n-hospital stay was 18  8 h.
ollow-up. A follow-up was obtained in all 202 patients
100 %) after a minimal duration of six months (mean 7 
months) (Table 4). At follow-up, six patients in the SES
roup and eight patients in the PES group had class II
ngina or greater (p  0.6). Eighteen patients in the SES
roup and 15 patients in the PES group underwent control
ngiography because they were reporting symptoms of
ypical or atypical angina pectoris or had undergone PCI of
lesion of particular prognostic value (left main, last
emaining vessel, and so on). The overall incidence of
ACE was low, 4% in the PES group versus 6% in the
ES group (including in-hospital MACE). No patient died
r experienced MI in either group after leaving the hospital.
arget lesion revascularization was required in three pa-
ients, one in the PES group and two in the SES group, and
ate stent thrombosis was documented in one patient of the
ES group. The event-free survival rate at six months was
6% in the PES group and 94% in the SES group (p 0.8).
ISCUSSION
o our knowledge this is the first randomized comparison
f two drug-eluting stents in the real world of routine
able 3. In-Hospital Complications
PES
Group
(n  100)
SES
Group
(n  102)
p
Value
eath 0 0 1.0
on–Q-wave MI 3 1 0.6
-wave MI 0 1 0.9
e-PCI 0 1 0.9
rgent CABG 0 0 1.0
tent thrombosis 0 0 1.0
bbreviations as in Tables 1 and 2.
able 4. MACE at Six Months (In-Hospital Complications
ncluded)
PES
Group
(n  100)
SES
Group
(n  102)
p
Value
eath 0 0 1.0
on–Q-wave MI 3 1 0.6
-wave MI 0 1 0.9
LR 1 2 0.9
ABG 0 1 0.9
tent thrombosis 0 1 0.9
vent-free included the
in-hospital outcome
96% 94% 0.8LR  target lesion revascularization; other abbreviations as in Table 1.linical practice. Our results confirm the excellent safety
rofile of both stents when used in various clinical and
natomic subsets. They compare favorably with those re-
orted in previous randomized trials in which event-free
urvival rates were 94% to 95% with the SES (3–5) and 89%
o 92% with the PES (8,9). Moreover, the present series is
n unselected cohort of patients, some of them with
igh-risk lesions such as left main stenosis, in-stent reste-
osis, or saphenous vein graft lesions, and nearly 30% with
iabetes. We were unable to show any difference between
he two stents, and the incidence of a MACE was very
imilar in both groups at six months. Angiographic control
as performed only in a minority of patients, and we may
ave underestimated the incidence of angiographic resteno-
is and silent stent thrombosis. However, even if such events
id occur, there is no evidence that they were more frequent
n either of the groups because the clinical outcomes were
imilar. On the other hand, relying on clinical follow-up
nly, we avoided potentially unnecessary target lesion revas-
ularization due to the occulostenotic reflex.
tudy limitations. Even if no difference between both
rug-eluting stents available on the market today could be
emonstrated in this prospective trial, a small advantage of
ne device over the other might exist but require a higher
umber of patients to reach any statistically demonstrable
ifference. Such a result would in any case be expected to
ave only limited impact on clinical practice. Our follow-up
uration is relatively short, and this represents a limitation,
s it implies failure to assess any potential (but unlikely) late
ifferences between both devices. Both these issues will
otentially be resolved in a definite manner when the results
f larger, ongoing randomized trials become available.
onclusions. Our data confirm that the excellent results
btained with drug-eluting stents in randomized trials can
e replicated in the real world of routine clinical practice
ithout any obvious detectable differences between the two
evices.
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